WO 2005/077431 PCT/GB2005/000471 21

## Claims

1 2 3

4

5

6

7

8

9

10

11

1. A method of producing a bioabsorbable, implantable substrate having a graded molecular weight distribution, comprising the steps of providing an implantable substrate and altering the molecular weight distribution of at least a portion of the implantable substrate by exposing that portion of the implantable substrate to electron beam irradiation.

12 13

14

15 16 2. A method as claimed in Claim 1 wherein the molecular weight distribution of the entire surface of the implantable substrate is altered by exposing the entire surface of the implantable substrate to electron beam irradiation.

18 19 20

21

22

23

24

25

26

17

3. A method as claimed in either one of Claims 1 and 2 wherein the implantable substrate is exposed to one or more doses of electron beam irradiation having an intensity of 0.1 to 10 MeV for 0.1 to 100 seconds and the electron beam irradiation penetrates 0.1 to 40 mm from the surface of the implantable substrate.

27 28

29

30

31 32 4. A method as claimed in any preceding claim wherein the implantable substrate is exposed to more than one dose of electron beam irradiation and each dose of electron beam irradiation is of a different intensity.

22

WO 2005/077431 PCT/GB2005/000471

1	5.	The method as claimed in Claim 4 wherein each
2		dose of electron beam irradiation penetrates
3		the implantable substrate to a different
4		depth.
5		
6	6.	A method of modifying the rate of
7		bioabsorbability of at least a portion of a
8		bioabsorbable, implantable substrate
9		comprising the step of exposing that portion
10		to electron beam irradiation.
11		
12	7.	A bioabsorbable, implantable substrate
13		obtainable according to the method of any
14		preceding claim.
15		
16	8.	A bioabsorbable implantable substrate
17		comprising a bioabsorbable polymer having a
18		graded molecular weight distribution through
19		at least a portion of its thickness.
20		
21	9.	The substrate of either one of Claims 7 and 8
22		wherein the rate of bioabsorbability of the
23		implant is predetermined.
24		
25	10	.The substrate of any one of Claims 7 to 9
26		having a graded molecular weight distribution
27		through the complete thickness of the
28		implantable substrate.
29		
30	11	.The substrate of any one of Claims 7 to 10
31		having an outer surface and a core wherein the
32		molecular weight distribution of the

WO 2005/077431 PCT/GB2005/000471

23

implantable substrate is greater at the core 1 than at the outer surface, and the rate of 2 bioabsorbability of the core is less than the 3 rate of bioabsorbability of the outer surface. 4 5 12. The substrate of Claim 11 wherein the outer 6 surface and the core of the bioabsorbable 7 implantable substrate are formed from the same 8 9 material. 10 13. The substrate of any one of Claims 7 to 12 1.1 being formed from polyglycolide (PGA), 12 polycaprolactone, polylactide (PLA), 13 poly(dioxanone) (PDO), poly(glycolide-co-14 trimethylene carbonate) (PGA-TMC), 15 polyanhydrides, poly(propylene fumarate), 16 polyurethane, copolymers thereof or a 17 combination thereof. 18 19 14. The substrate of any one of Claims 7 to 13 in 20 the form of an interference screw, suture 21 anchor, bioresorbable polymer composite, or a 22 bioabsorbable scaffold for tissue regeneration 23 and growth. 24 25 15.A method of treatment of a disorder of or 26 damage to hard or soft tissue comprising the 27 step of implanting the substrate of any one of 28 Claims 7 to 14 into a human or animal body. 29 30 16.A method of treatment as claimed in Claim 15 31 wherein the disorder is osteo- or rheumatoid 32

WO 2005/077431 24

1	arthritis, osteoporosis, inflammatory,
2	neoplastic, traumatic or infectious tissue
3	conditions, syndromes characterised by
4	chondrodysplasia, cartilage damage, fracture,
5	ligament tears, hernia, synovitis, systemic
6	lupus erthematosus, or wounds sustained during
7	surgery.
8	
9	17. The substrate of any one of Claims 7 to 15 for
10	use in therapy.
11	
12	18. The use of the substrate of any one of Claims
13	7 to 14 in the manufacture of a medicament for
14	the repair or treatment of disorders of or
15	damage to hard or soft tissue of the human or
16	animal body.
17	
18	
19	
20	
21	

PCT/GB2005/000471